3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Prostatic Neoplasms
5
Urinary Bladder Neoplasms
4
Melanoma
4
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Sarcoma
2
Ovarian Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Merkel Cell
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Plasma Cell
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, T-Cell, Cutaneous
1
Lung Neoplasms
1
Kidney Neoplasms
1
Chondrosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Hepatocellular
1
Adenocarcinoma
1
Interventions
pembrolizumab
92
Gemcitabine
56
Nivolumab
50
Cisplatin
39
atezolizumab
37
Carboplatin
30
avelumab
29
enfortumab vedotin
26
Docetaxel
23
Magnetic Resonance Spectroscopy
19
Mitomycin
17
Ipilimumab
17
Paclitaxel
16
Specimen Handling
14
durvalumab
11
toripalimab
10
sacituzumab govitecan
10
Pemetrexed
10
cabozantinib
9
Taxes
8
vinflunine
7
Cyclophosphamide
7
tislelizumab
6
Injections
6
Bevacizumab
6
pemigatinib
5
fludarabine
5
disitamab vedotin
5
Standard of Care
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
poly ICLC
×
Genitourinary
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled